Abstract Plasma concentrations of cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein (apo) B, and lipoprotein(a) (Lp[a]) in 46 persons heterozygous for the apo B-3500 mutation causing familial defective apo B-100 (FDB) were compared with those in 57 non-FDB relatives. FDB patients had 50% to 70% higher mean concentrations of cholesterol, LDL cholesterol, and apo B than non-FDB relatives (P<W 4 for all three variables). Triglycerides were higher (P=.O16) and HDL cholesterol was lower (P=.O21) in FDB patients. The concentration ranges of these variables were broad in each family, and there was no betweenfamily difference in means for cholesterol and LDL cholesterol. There was no phenotype-specific difference in Lp(a) concentrations between FDB patients and non-FDB relatives. Apo E4 is normally associated with higher concentrations of LDL and apo E2 with lower concentrations. This relation was partly reversed in FDB patients: apo E4 was associated with lower apo B concentrations and apo E2 with higher apo B concentrations. Tendon xanthomata were found in members of two of the five families. Six of 12 FDB patients >50 years old had atherosclerotic disease. In contrast, all 18 non-FDB relatives >50 years old were apparently healthy. A total of 8 FDB patients with atherosclerotic disease had 36% higher cholesterol concentrations, 28% higher apo B concentrations, 50% higher triglyceride concentrations, and 120% higher Lp(a) concentrations than FDB patients without clinical atherosclerosis. The haplotype background for the apo B-3500 mutation in these Danish families, as defined with seven markers, was comparable to that found in kindreds from the
fied on the basis of a certain lipoprotein profile (ie, familial hypercholesterolemia or type Ila hyperlipidemia) or manifest atherosclerotic disease. As discussed by the authors, 7 the results are therefore likely to be biased by the selection method.
Comparison of biochemical and clinical phenotypes in FDB subjects and non-FDB subjects from the same families, in which environmental and other genetic factors are more similar than in a cross-sectional sample of unrelated subjects, reduces this selection bias toward specific phenotypes. The risk of bias is not eliminated, however, since index persons with a family history of severe hypercholesterolemia or atherosclerotic disease are more likely to be identified than persons without such a history. The most unbiased and informative sampling strategy would be family studies through index persons identified from a randomly selected population. Since the prevalence of this mutation seems to be between 1/700 and 1/1000, a large population must be screened to get a reasonable number of index persons and informative families.
With these caveats, the purpose of the present study was to assess the impact of the mutation on clinical and lipid and lipoprotein variables in families harboring the FDB mutation by comparing FDB subjects with non-FDB relatives.
Methods Subjects
Five index persons were identified by screening DNA for the apo B-3500 mutation in a large number of patients with hypercholesterolemia. Two index persons had been diagnosed as having familial hypercholesterolemia on the basis of criteria including tendon xanthomata and elevated LDL cholesterol. Two index persons were identified by screening patients in an outpatient clinic for hyperlipidemic patients, and the last index person was identified by screening 445 Danish participants in a multicenter study of simvastatin treatment of patients with ischemic heart disease and moderate hypercholesterolemia (the Scandinavian Simvastatin Survival Study [4S Study]). 8 A total of 103 genetically related members of the five families were examined (46 FDB heterozygotes and 57 non-FDB relatives).
Detection of the Apo B-3500 Mutation
Genomic DNA was prepared from whole blood cells as described by Kunkel et al. 9 Screening for the mutation was performed with a polymerase chain reaction (PCR)-based assay with a mutagenic sense primer and subsequent cleavage by Msp I followed by size separation by gel electrophoresis as previously described.
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Haplotype Markers
All persons were genotyped for the following seven polymorphic alleles in or near the apo B gene: a 9-bp insertion/ deletion polymorphism in the signal peptide coding region (Ins/Del), 11 aPvu II restriction fragment length polymorphism (RFLP) in intron 4, 12 an Alu I RFLP in exon 14, 12 an Xba I RFLP in exon 26, an Msp I RFLP in exon 26, an EcoRl RFLP in exon 29, 13 and a 3' variable number of tandem repeats (VNTR) polymorphism. 1415 All polymorphic markers were determined after PCR amplification by restriction enzyme digestion and/or size separation by gel electrophoresis as described in Hansen et al 16 and Ludwig and McCarthy. 17 The lengths of the 3'VNTR fragments were determined by plotting the migration distance by gel electrophoresis to a standard curve on semilogarithmic paper made from the migration distance of a DNA size standard (Bio-Rad catalog No. 170-3465), and the number of repeats was calculated as described by Boerwinkle et al.
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Apo E Genotyping All persons were genotyped as described by Hixson and Vernier. 19 Briefly, the part of the apo E gene spanning the polymorphic sites at codons 112 and 158 was amplified by PCR and cleaved by Cfo I (isoschizomer Hha I). The cleavage products were then separated according to size by gel electrophoresis.
Lipoprotein(a) (Lp[a]) Concentration and Phenotype
Plasma concentrations of Lp(a) were measured by a commercial two-site immunoradiometric assay (Pharmacia Diagnostics AB, Uppsala, Sweden) as previously described. 20 All measurements were done with the same batch of reagents. Lp(a) protein phenotyping was also performed as previously described. 20 Briefly, lipoproteins in whole plasma were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and apo(a) isoforms were identified by immunoblotting with a monoclonal antibody specific to apo(a). The phenotypes were designated according to their relative mobility compared with apolipoprotein B as proposed by Utermann et al 21 : F, faster than apo B; B, same mobility as apo B; and S!-S 4 , increasingly lower mobility than apo B.
Lipids
Plasma was collected after an overnight fast. None of the persons examined used drugs or diet to lower plasma lipids. Cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured by standard enzymatic procedures (Boehringer Mannheim GmbH; catalog No. 310328, 701912, and 543004). LDL cholesterol was calculated by the Friedewald formula. 22 Apo B concentration in plasma was measured by a commercial immunoradiometric assay (Pharmacia). All measurements were done with the same batch of reagents.
Statistical Analyses
Because triglycerides and Lp(a) concentrations were skewed to the left, statistical tests were done either on log^-transformed concentrations (triglycerides) or by nonparametric methods (triglycerides and Lp[a]). Differences in mean concentrations of lipids and apolipoproteins between FDB and non-FDB subjects were tested by the Mann-Whitney twosample test. Between-family differences in means of the variables measured in FDB subjects were tested by the KruskalWallis test of several group means. Differences in means of the measured traits in FDB subjects by sex or age (grouped in decades) were tested by the Mann-Whitney two-sample test or the Kruskal-Wallis test of several group means. The contribution of variation in the apo E gene to variation in lipid and apolipoprotein concentrations was tested by the KruskalWallis test of several group means in FDB and non-FDB subjects separately. Plasma cholesterol concentrations in FDB subjects were compared for different age groups with the 95th percentile for corresponding age groups of the general Danish population.
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- 24 We performed all analyses in the whole material as well as after exclusion of index persons. Since this exclusion did not affect results, results are given for the whole material.
Results
The age and sex composition of each family is given in Table 1 , together with information on atherosclerotic disease and extravascular cholesterol deposits. In all five families, there was at least one person with arcus corneae or xanthelasmata, whereas tendon xanthomata were detected only in members of the two families whose index persons originally were classified as having familial hypercholesterolemia. No non-FDB subjects had any signs of extravascular cholesterol deposits. Four FDB patients had ischemic heart disease, 2 had peripheral artery disease (intermittent claudication), and 2 had both ischemic heart disease and intermittent claudication (Table 1) . No non-FDB relatives had any history of atherosclerotic disease.
Mean concentrations of cholesterol, LDL cholesterol, and apo B differed significantly between FDB and non-FDB subjects (Table 2 ), but there was some overlap in ranges. There were higher mean values of cholesterol, LDL cholesterol, and apo B in FDB than in non-FDB subjects in all age groups, with some overlap, except for LDL cholesterol in the youngest age group (Table 3) . Compared with the Danish background population, 23 - 24 the mean values in mutation carriers were above the 95th percentile for cholesterol except for the youngest age group, in which mean cholesterol levels were close to the 95th percentile.
There were no between-family differences in mean cholesterol or LDL cholesterol concentrations in FDB patients (Table 2 ). In most of the families, triglycerides tended to be higher and HDL cholesterol lower in FDB than in non-FDB subjects (Table 2 ). These differences were significant when data from all five families were pooled.
There was no difference in plasma concentrations of Lp(a) between FDB and non-FDB subjects ( FDB indicates familial defective apolipoprotein B-100; IHD, ischemic heart disease; and PAD, peripheral artery disease.
of the low number of subjects in most of the statistical cells, the apo(a) phenotypes were grouped according to size into four groups as previously described 20 : group 1, apo(a) phenotypes F, B, and S x ; group 2, apo(a) phenotypes S 2 , S 2 S 3 , and S 2 S 4 ; group 3, apo(a) phenotypes S 3 , S 4 , and S 3 S 4 ; group 4, apo(a) null phenotype. There was no phenotype-specific difference in Lp(a) concentrations between FDB and non-FDB subjects, either (P=.l to .7; data not shown).
Mean cholesterol, LDL cholesterol, and apo B concentrations in different apo E genotype groups are given in Table 4 . Because of low numbers, E4/4 and E2/2 genotypes were excluded from analysis. In non-FDB relatives, apo E polymorphism contributed significantly to the variation in mean concentrations of LDL cholesterol and insignificantly to the variation in mean apo B concentrations. E3/4 persons (n=13) had high values, E3/2 (n = 15) had low values, and E3/3 (n=22) had intermediate values. In contrast, FDB subjects with E3/4 (n=12) had the lowest apo B concentrations and E3/2 (n = 8) the highest apo B concentrations, with intermediate concentrations in E3/3 individuals (n=24). The apo E polymorphism was also associated with differences in the ratio of LDL to apo B in patients with FDB: E4 subjects had the highest, E2 subjects the lowest, and E3 subjects intermediate values (Table 4) .
Using the seven haplotype markers, we could deduce the genetic background for the mutation in all five families as Ins/Xba l-/Msp l+IEcoRl-/Alu l-/Pvull-/ 3'VNTR-49, which is identical to the haplotype results from a study of eight kindreds from Dallas, San Francisco, Montreal, Salzburg, and Milan, except that one of these eight kindreds differed by having 48 instead of 49 repeats at the 3'VNTR region. 17 In FDB subjects >50 years old, 6 of 12 had either ischemic heart disease, peripheral artery disease, or both (Table 5) . We examined the lipid and lipoprotein patterns in all 8 FDB subjects with atherosclerotic disease (Table 5 ). FDB subjects with the four highest cholesterol concentrations in the whole group were in this group, and FDB subjects with atherosclerotic disease had higher mean cholesterol levels than did FDB subjects without clinical atherosclerosis (9.71 versus 7.12 mmol/L; P=.0Q2). The mean apo B concentration was also higher (1.76 versus 1.38 g/L; P=.O15). These 8 persons also had higher mean triglyceride concentrations than FDB subjects without clinical atherosclerosis (2.0 versus 1.35 mmol/L; P=.O7). Moreover, median plasma concentrations of Lp(a) were significantly higher in FDB subjects with atherosclerotic disease than in those without atherosclerotic disease (20.2 versus 9.2 mg/dL;P=.05).
Discussion
In this study, patients with the apo B-3500 mutation had 50% to 70% higher levels of plasma cholesterol, LDL cholesterol, and apo B than non-FDB relatives.
However, approximately 30% of FDB subjects have cholesterol concentrations below the 95th percentile for age in the general Danish population. The broad range of lipid concentrations in FDB subjects suggests that environmental or other genetic factors modify the effect of the apo B-3500 mutation on plasma lipids. The apo B-3500 mutation causes elevated lipid concentrations from childhood (Reference 7 and this study), and, like familial hypercholesterolemia, it causes premature atherosclerosis. Thus, it is important to diagnose the condition, but the broad range of cholesterol and apo B concentrations in these patients makes these measurements diagnostically unreliable. Screening for the mutation in persons with a family history of hypercholesterolemia or atherosclerotic disease, despite only modestly elevated cholesterol levels, should therefore be considered. Screening can be done specifically and reliably from very small blood samples like Guthrie spots. 10 The more unfavorable lipid and lipoprotein pattern in FDB subjects with atherosclerotic disease than in those without atherosclerotic disease (Table 5) suggests that other genetically determined (Lp[a] ) or genetically and environmentally determined (triglycerides) risk factors substantially aggravate the risk of atherosclerotic disease caused by the apo B-3500 mutation.
In all the families, triglycerides were higher and HDL cholesterol was lower in FDB subjects, and this difference was significant in the group as a whole (Table 2) . Since triglycerides are transported mainly in VLDL and VLDL remnant lipoproteins, these findings may be caused by lower catabolic rates of VLDL and VLDL remnants as well as LDL in FDB. However, this hypothesis needs to be confirmed by metabolic studies.
The possible role of the LDL receptor in Lp(a) catabolism is not clear. 2529 If Lp(a) is catabolized by this route, Lp(a) concentrations would be expected to be higher in FDB subjects, because the mutant apo B in Lp(a) would be expected to delay Lp(a) interaction with the receptor. Our data do not support this concept.
Apo E mediates binding of VLDL and VLDL remnants to the LDL receptor. The apo E protein is polymorphic, 30 -31 with three common variants (E2, E3, and E4). In the general population, the E4 variant is associated with higher and the E2 variant with lower plasma concentrations of cholesterol and apo B, both compared with E3 homozygotes.
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The 57 non-FDB members of our five families had the expected association of apo E polymorphism with lipid variation, but in FDB subjects, there was no such association. On the contrary, E3/4 persons had the lowest and E3/2 persons the highest concentrations of apo B (Table 4) . Downregulation of hepatic LDL receptors caused by increased catabolism of E4-containing lipoproteins, which has been suggested as the physiological basis of the higher cholesterol and apo B concentrations in E4 subjects than in E3 homozygotes, 35 may not happen in FDB, since the proportion of LDL with normal binding properties to the LDL receptor is low in this condition (approximately 25%). This may explain why FDB subjects with the e 4 allele have lower apo B concentrations than e 3 homozygotes. Conversely, the low affinity of the E2 protein to the LDL receptor, which, in normal subjects, is thought to induce a compensatory upregulation of the LDL receptor and an increased catabolism of lipoproteins caused by binding of apo B to the receptor, 33 -34 would not be expected to decrease the concentration of apo B-containing lipoproteins, since both ligands interact poorly with the receptor. Instead, the E2 apolipoprotein would add further to the elevation of apo B-containing lipoproteins. The higher ratio of LDL cholesterol to apo B in FDB subjects with an e4 allele than in FDB subjects with an el allele (Table 4) is consistent with this explanation, since a decreased fractional clearance rate by the LDL receptor is associated with the accumulation of relatively protein-rich LDLs. The identical haplotype background for the apo B-3500 mutation in these Danish families with that in several other kindreds of Caucasian origin further supports the contention that the mutation in different families has a common founder and that the mutation is restricted to Caucasians.
